EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study

Phornpaka Ueapornpanith iD, Boonyanuch Buranakiti iD, Thanyalak Chotayaporn, Arintaya Phrommintikul, Voratima Yoodee iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0289721 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Phornpaka Ueapornpanith und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Acute Coronary Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From the restriction of access to primary percutaneous coronary intervention, about 46% of patients with ST-elevation acute coronary syndrome (STE-ACS) received fibrinolytic therapy as a reperfusion strategy; streptokinase is frequently used in Thailand. Despite the guidelines recommending potent P2Y 12 inhibitors among these patients, the data are limited, especially among patients with STE-ACS post streptokinase therapy. The study was proposed to describe factors for P2Y 12 inhibitors selection and evaluate outcomes of pharmacoinvasively treated STE-ACS receiving ticagrelor compared with clopidogrel in Thailand. We performed a retrospective observational study of patients with STE-ACS post streptokinase therapy followed by percutaneous coronary intervention (PCI) with coronary stent placement and receiving ticagrelor or clopidogrel as P2Y 12 inhibitor treatment from January 2017 to June 2021. The primary outcomes described factors for P2Y 12 inhibitor selection and evaluated safety outcomes with inverse probability weight (IPW) adjustment. The secondary outcome was a composite of all-cause death, myocardial infarction and stroke. The median time from streptokinase therapy to initiating ticagrelor in the switch group was 25.7 (IQR, 1.9–4.4) hours. The factors related to switching from clopidogrel to ticagrelor included young age, history of coronary artery disease (CAD), dose of streptokinase and use of intravascular imaging. Any bleeding events occurred among 83 patients (41.71%) in the switch group and 83 patients (41.09%) in the no switch group (adjusted HR 1.04, 95% CI 0.75–1.44; p = 0.826). The composite of efficacy outcomes occurred in 6 patients in the switch group (3.02%) and 12 patients (5.94%) in the no switch group (adjusted HR 0.57, 95% CI 0.21–1.57; p = 0.279). Conclusion: In real practice, ticagrelor switching among patients with STE-ACS post streptokinase therapy did not differ regarding safety outcomes and composite of efficacy outcomes compared with clopidogrel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionAcute Coronary SyndromeHumansTicagrelorClopidogrelPlatelet Aggregation InhibitorsStreptokinaseTreatment OutcomePurinergic P2Y Receptor AntagonistsPrasugrel Hydrochloride

Substanzen

TicagrelorClopidogrelPlatelet Aggregation InhibitorsStreptokinasePurinergic P2Y Receptor AntagonistsPrasugrel Hydrochloride

Autor:innen und Institutionen

  • Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
  • Pharmacy Department, Nakornping Hospital, Chiang Mai, Thailand.
  • Department of Internal Medicine, Nakornping Hospital, Chiang Mai, Thailand.
  • Faculty of Medicine, Department of Internal Medicine, Division of Cardiology, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: Phornpaka Ueapornpanith, Boonyanuch Buranakiti, Voratima Yoodee

Zitieren

APA

Ueapornpanith, P., Buranakiti, B., Chotayaporn, T., Phrommintikul, A., & Yoodee, V. (2023). Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study. PLOS ONE. https://doi.org/10.1371/journal.pone.0289721

Vancouver

Ueapornpanith P, Buranakiti B, Chotayaporn T, Phrommintikul A, Yoodee V. Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study. PLOS ONE. 2023. doi:10.1371/journal.pone.0289721

BibTeX
@article{Ueapornpanith2023,
  author = {Ueapornpanith, Phornpaka and Buranakiti, Boonyanuch and Chotayaporn, Thanyalak and Phrommintikul, Arintaya and Yoodee, Voratima},
  title = {Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0289721}
}
Kostenlos starten →